GW Unit New Epidiolex (cannabidiol) Data at American Epilepsy Society

GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, along with U.S. subsidiary Greenwich Biosciences, today presented new data from a Phase 3 clinical trial of EPIDIOLEX^® (cannabidiol or CBD) oral solution, CV in tuberous sclerosis complex (TSC) at the American Epilepsy Society (AES) Annual Meeting. The study found that patients treated with EPIDIOLEX 25 mg/kg/day or 50 mg/kg/day experienced a significantly greater reduction in TSC-associated seizures (49% for 25 mg/kg/day and 48% for 50 mg/kg/day) compared to placebo (27%; p=0.0009 and p=0.0018, respectively).

https://www.marketscreener.com/GW-PHARMACEUTICALS-PLC-13112125/news/Greenwich-Biosciences-a-GW-Pharmaceuticals-Company-Presents-New-Data-for-EPIDIOLEX-cannabidiol-29697544/